Therapeutic interventions that stop or reverse age-related damage in specific organs or tissues, or for age-related diseases.
Towards the end of last year, we unveiled the Ten Levels of Longevity framework, a detailed and structured guide designed to navigate the growing field of longevity science. Following on from our discussion of Level 6, which focused on clinical interventions that control aging drivers to prevent aging diseases from occurring, we now move to Level 7: targeted aging disease reversal.
Level 7: Targeted aging disease reversal
Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases.
Targeted aging disease reversal encompasses therapeutic strategies aimed at halting or reversing the damage caused by aging within specific organs or tissues. Unlike preventive approaches, this level focuses on restoring function and vitality to areas already affected by age-related decline.
Techniques such as induced pluripotent stem cell (iPSC) therapies are being developed to regenerate tissues in key organs, offering the potential to rejuvenate heart, liver or brain function by replacing damaged cells with healthy ones. Additionally, partial cellular reprogramming seeks to reverse cellular aging without altering the cell’s identity, thereby promoting the regeneration of entire organs in vivo.
Investment opportunities in targeted aging disease reversal
The field of targeted aging disease reversal presents compelling investment opportunities, particularly in companies pioneering partial cellular reprogramming. These firms aim to rejuvenate cells within specific tissues, thereby restoring organ function and reversing disease progression. Investors are increasingly interested in biotechnologies that can safely reset cellular age without compromising cellular identity, as these approaches hold promise for treating a range of age-related diseases. The potential for high returns is significant, given the transformative impact these therapies could have on healthcare and aging.
Companies active at Level 7
Cellvie
Cellvie is a biotech focusing on Therapeutic Mitochondria Transplantation (TMT). This innovative approach involves isolating healthy mitochondria, the energy powerhouses of cells, and introducing them into cells compromised by ischemia, such as those affected by heart attacks or kidney transplants. By replenishing these damaged cells with functional mitochondria, Cellvie aims to restore cellular energy metabolism and potentially improve organ function. While initially focused on ischemia-reperfusion injuries, the company envisions expanding their technology to address other age-related conditions linked to mitochondrial dysfunction, positioning them as a potential player in the longevity field.
Altos Labs
Altos, a biotech led by CEO Hal Barron, focuses on reversing cellular aging. Backed by Jeff Bezos and ARCH Venture Partners, it aims to reprogram cells to a more youthful state using techniques like induced pluripotent stem cells (iPSCs) and nuclear transfer. Altos Labs’ work aligns with Level 7 of the aging disease management framework, as they are actively exploring ways to reverse aging-related damage in specific organs, potentially leading to significant breakthroughs in longevity and antiaging medicine.
Longeveron
Clinical-stage biotech Longeveron is developing regenerative medicine therapies using mesenchymal stem cells (MSCs). These cells possess signaling properties to promote tissue repair and reduce inflammation. Longeveron focuses on treating age-related diseases such as hypoplastic left heart syndrome, Alzheimer’s disease and frailty by leveraging the regenerative potential of MSCs. By targeting these specific conditions, Longeveron aims to improve patient outcomes and extend healthspan.
Shift Bioscience
Shift is a longevity company focused on developing cellular reprogramming therapies to reverse aging and age-related diseases. Led by CEO Daniel Ives, they use machine learning to identify and target key pathways involved in cellular aging. While they don’t offer direct treatments yet, their pipeline includes programs exploring safe methods to reset cells and tissues to a more youthful state. This approach has the potential to reverse or slow down cellular aging throughout the body, promoting healthy lifespan and potentially preventing age-related diseases.
Retro Biosciences
Retro Biosciences is a biotech led by CEO Joe Betts-LaCroix; it focuses on developing therapies to prevent and treat age-related diseases, and recently used OpenAI’s custom protein model called GPT-4b to improve the efficiency of stem cell reprogramming. Their pipeline includes drug candidates for conditions like Alzheimer’s disease and age-related macular degeneration. Their goal is to develop preventative therapies that could potentially delay the onset of age-related diseases and extend healthy lifespan.
Telocyte
Telocyte is a company focused on “a future beyond Alzheimer’s” and is researching a potential cure for the debilitating neurodegenerative disease. Telocyte believes that aging cells recycle molecules too slowly, leading to amyloid plaque buildup in the brain. Unlike current therapies that focus on symptoms, the company aims to address the root cause by resetting abnormal gene expression, an approach that could, potentially, offer a new approach to treating Alzheimer’s and other age-related diseases.
The advancements in Level 7, targeted aging disease reversal, represent a significant leap forward in longevity science. By focusing on restoring function to specific organs and tissues, these therapies hold the promise of not only extending lifespan but also enhancing the quality of life in later years.
Check out our look at Levels 1 (lifestyle management), 2 (consumer diagnostics), 3 (longevity supplements), 4 (longevity clinics), 5 (aging disease management) and 6 (aging disease prevention therapeutics) HERE and stay tuned for Levels 8 to 10 coming over the next few weeks!
